Literature DB >> 21263459

Clinical guidelines: Expert recommendations for NSAID use: a user-friendly model?

Steven B Abramson1.   

Abstract

Although tens of millions of individuals worldwide use nsaids daily, balancing the competing risks and benefits of these agents continues to be a challenge. Evidence-based treatment guidelines and expert opinions have been promulgated, but will they actually translate to improved patient care? A new Web-based tool could aid physicians' treatment decision-making.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21263459     DOI： 10.1038/nrrheum.2010.230

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  7 in total

1.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

2.  Characteristics of older adults receiving opioids in primary care: treatment duration and outcomes.

Authors:  M Carrington Reid; Charles R Henderson; Maria Papaleontiou; Leslie Amanfo; Yelena Olkhovskaya; Alison A Moore; Sagar S Parikh; Barbara J Turner
Journal:  Pain Med       Date:  2010-07       Impact factor: 3.750

3.  Coxibs and NSAIDs--is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007.

Authors:  R W Moskowitz; S B Abramson; F Berenbaum; L S Simon; M Hochberg
Journal:  Osteoarthritis Cartilage       Date:  2007-07-23       Impact factor: 6.576

4.  Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper.

Authors: 
Journal:  Arthritis Rheum       Date:  2008-08-15

5.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

6.  Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.

Authors:  Henry Krum; Sean P Curtis; Amarjot Kaur; Hongwei Wang; Steven S Smugar; Matthew R Weir; Loren Laine; D Craig Brater; Christopher P Cannon
Journal:  Eur J Heart Fail       Date:  2009-04-19       Impact factor: 15.534

7.  The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.

Authors:  Gerd Burmester; Angel Lanas; Luigi Biasucci; Matthias Hermann; Stefan Lohmander; Ignazio Olivieri; Carmelo Scarpignato; Josef Smolen; Chris Hawkey; Adam Bajkowski; Francis Berenbaum; Ferdinand Breedveld; Peter Dieleman; Maxime Dougados; Thomas MacDonald; Emilio Martin Mola; Tony Mets; Nele Van den Noortgate; Herman Stoevelaar
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.